Opiant Pharmaceuticals, Inc. OPNT
20.65 +20.65
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 21.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 2
- 2 months ago 2
- 3 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.21 | -1.21 – -1.21 | 0.11 | -1200.0% | 1.80M | -87.0% | 1 |
| Next quarter | -2.14 | -2.14 – -2.14 | -2.43 | +11.9% | 2.30M | -48.5% | 1 |
| Current year | -6.04 | -6.04 – -6.04 | 0.51 | -1284.3% | 9.00M | -81.2% | 1 |
| Next year | -4.23 | -4.23 – -4.23 | -6.04 | +30.0% | 26.30M | +192.2% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2021 | Oppenheimer | Initiated | — | Outperform |
| Sep 28, 2018 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jun 12, 2018 | Cantor Fitzgerald | Initiated | — | Overweight |
| May 5, 2018 | B. Riley FBR | Downgrade | Buy | Neutral |
| Nov 30, 2012 | Mizuho | Downgrade | Buy | Neutral |
| Oct 31, 2012 | Evercore Partners | Downgrade | Overweight | Equal-Weight |
| Aug 8, 2012 | Wedbush | Maintained | — | Neutral |